ALXO - ALX Oncology announces the end of post-grant review period for key patent

The post-grant review period for the granted U.S. Patent No. 10,696,730 ended on March 30, 2021, ALX Oncology Holdings ([[ALXO]] +1.0%) announced today.The patent trial and appeal board can initiate a post-grant review process if a third party files a petition during the nine-month-long period following the grant of the patent.Issued on June 30, 2020, U.S. Patent No. 10,696,730 covers ALX Oncology’s lead product candidate ALX148 and is valid until August 5, 2036 subject to patent term adjustments or extensions, the company said.“The USPTO’s issuance of this patent reinforces the strength of our intellectual property portfolio,” commented CEO of ALX Oncology, Jaume Pons.“We are excited about the grant of the ‘730 patent and the expiration of the post-grant review period as we prepare to initiate randomized Phase 2 studies in myelodysplastic syndromes, gastric/gastroesophageal junction cancer, and head and neck squamous cell carcinoma.In October, ALX Oncology announced the dosing initiation in a Phase 1/2

For further details see:

ALX Oncology announces the end of post-grant review period for key patent